Advertisement
(Logo: http://www.newscom.com/cgi-bin/prnh/20031202/BECLOGO)
All of the sequencing work and data generation for the study were done byAgencourt's Genomic Services, which has a long-standing relationship with theJohns Hopkins Kimmel Cancer Center scientists.
Advertisement
According to a news release issued by the Johns Hopkins Kimmel CancerCenter, scientists involved in the study found that most cancer-causing genemutations are quite diverse and can vary from person to person. Of the 70 to80 genes that are mutated in an individual cancer, about 15 are likely tocontribute to the cancer's key characteristics, and most of these genes aredifferent for each patient. With no more higher-frequency mutations (such asp53) on the horizon, researchers can focus on these less-commonly mutatedgenes and the complicated protein pathways that link them. Personalized cancergenomic research paves the way for tailored therapies and diagnostics focusingon the alterations identified in a particular patient's cancer.
"The research findings have important implications in the development ofpersonal genomics, including molecular diagnostic tests, which are of greatinterest to Beckman Coulter," commented Erick Suh, Genomic Services directorfor Agencourt. "As the leading provider of DNA sequencing services, we havedeveloped strong relationships with leading cancer research teams such asJohns Hopkins and are proud to contribute to these scientific advancements."
Agencourt Bioscience Corporation, a wholly owned subsidiary of BeckmanCoulter, is a leading provider of nucleic acid purification products andgenomic services for life science research. The company's products andservices are based on the patented Agencourt SPRI(R) (Solid Phase ReversibleImmobilization) paramagnetic bead-based technology.
Beckman Coulter, Inc., based in Fullerton, California, develops,manufactures and markets products that simplify, automate and innovate complexbiomedical tests. More than 200,000 Beckman Coulter systems operate inlaboratories around the world supplying critical information for improvingpatient health and reducing the cost of care. Recurring revenue, consistingof supplies, test kits, service and operating-type lease payments, representsmore than 75 percent of the company's 2006 annual revenue of $2.53 billion.For more information, visit http://www.beckmancoulter.com.
To view the Johns Hopkins Kimmel Cancer Center news release please copyand paste the following link into your browser:http://www.hopkinskimmelcancercenter.org/news/index.cfm?documentid=931&newstype=News%20Releases&action=showthisitemContacts: Jennifer Dahlgren, Dahlgren Communications Phone: (530) 265-0538 E-mail: [email protected] Lynn Doucette-Stamm, Ph.D. Agencourt Bioscience Corporation Phone: (978) 867-2670 E-mail: [email protected]
SOURCE Agencourt Bioscience Corporation
